SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending significantly following news of a substantial investment from the U.S. government, which includes a 10% equity stake and a large loan package, implying a much higher valuation for the company. The community is highly optimistic, discussing potential price surges and a massive short squeeze, viewing this as a pivotal move to secure domestic rare earth supply chains and reduce reliance on China.

The KARATE token is the official digital currency in the KarateDAO and it gives fans the power to vote to support their favorite fighters, vote on upcoming fights, take part in prize pools, and join exclusive events via Karate Combat's Up Only Gaming App.

Karate Combat

Karate Combat is trending as a pioneer in Web3 sports, generating buzz for its UP Layer 2 blockchain platform on Hedera and the upcoming $UP token, designed to reward $KARATE stakers and enhance fan engagement. The community is highly bullish, viewing it as an undervalued 'gem' given its unique blend of live, immersive fights with gamified features like no-loss betting. Enthusiasts anticipate significant growth as this crypto-native fight league expands its reach and ecosystem.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics Inc.

Palvella Therapeutics Inc

Palvella Therapeutics is generating significant buzz following positive Phase 2 trial results for its QTORIN rapamycin gel in cutaneous venous malformations, a rare skin condition with no approved treatments. This clinical success, coupled with a recent Fast Track designation and a "pipeline-in-a-product" strategy targeting multiple rare dermatological indications, is driving numerous analyst upgrades and high price targets. The community is actively debating the stock's future, weighing potential dilution against the substantial market opportunity and upcoming Phase 3 data for another indication.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 Inc. (DXYZ) is trending due to intense speculation surrounding a potential SpaceX IPO and recent upward revisions to its private valuation, a key holding in the fund. The community is actively discussing DXYZ's substantial exposure to other high-profile private tech firms like OpenAI, fueling anticipation for significant gains. However, this bullish sentiment is counterbalanced by ongoing concerns regarding the fund's notable trading premium compared to its underlying net asset value.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife ($CAW) is trending with an extremely active community rallying behind its multichain presence across networks like Cronos, Solana, and Base. Enthusiasts are highlighting its unique deflationary burn mechanism, which triggers with each bridge transaction, positioning it as a significant player aiming to drive volume and market shifts. The community expresses strong conviction, touting it as the "real deal" and the "king of the memes" that's "built different" from typical meme coins.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Cronos (CRO) is trending due to several strategic developments, including Trump Media Group's plan to integrate CRO for digital token distribution and new partnerships expanding into prediction markets and proposed ETFs with 21Shares US. While a segment of the community views these as strong catalysts for future growth and increased ecosystem utility, others express frustration over the token's recent performance compared to the broader crypto market.

CPS Technologies Corp. engages in the provision of advanced material solutions to the transportation, automotive, energy, computing or Internet, telecommunications, aerospace, defense, and oil and gas end markets. The firm focuses on the design, manufacture, and sale of custom metal matrix composite components. It also assembles housings and packages for hybrid circuit. The company was founded in 1984 and is headquartered in Norton, MA.

CPS Technologies Corporation

CPS Technologies is trending amid strong community anticipation for significant contract updates and material news, with recent discussion focusing on its critical role in defense, nuclear energy, and AI data center infrastructure. Investors are highlighting the company's multiple US government contracts and its strategic positioning with advanced composite materials as key drivers for potential future growth. Chatter around increased insider buying and a planned facility expansion further bolsters confidence in its long-term prospects.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp Developments is trending due to reports of significant institutional ownership increases, including BlackRock and Citadel, alongside positive drill results confirming high-grade critical minerals at its Nebraska project. The company's recent acquisition of alloy manufacturing assets is also signaling a move towards vertical integration, positioning it as a key domestic supplier. The community is actively discussing the strategic importance of NB's niobium, scandium, and rare earths for U.S. defense and technology, eagerly anticipating an updated feasibility study and EXIM loan approval as major catalysts for a potential re-rating.

American Homes 4 Rent is a real estate investment trust. It engages in the acquisition, renovation, leasing, and operating of single-family homes as rental properties. The company was founded by Bradley Wayne Hughes, Sr. on October 19, 2012 and is headquartered in Las Vegas, NV.

American Homes 4 Rent - Ordinary Shares - Class A

American Homes 4 Rent is trending amidst an executive order proposing restrictions on institutional investors from purchasing single-family homes to address housing affordability. The community is actively debating the potential impact on the company, with many users arguing that AMH primarily builds new homes rather than acquiring existing ones, suggesting it might be less directly affected than other institutional players in the housing market.

American Exceptionalism Acquisition Corp. A is a blank check company. It was created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on July 11, 2025 and is headquartered in Menlo Park, CA.

American Exceptionalism Acquisition Corp. A - Ordinary Shares - Class A

American Exceptionalism Acquisition Corp. A

American Exceptionalism Acquisition Corp. (AEXA) is trending amidst feverish speculation for an imminent merger announcement, with market participants eagerly debating potential high-growth targets in sectors like AI, defense, and energy. Led by controversial sponsor Chamath Palihapitiya, the stock sees significant trading activity as investors weigh the potential for a 'life-changing' deal against the inherent risks of a speculative SPAC.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Predictive Oncology Inc. (POAI) drew significant interest from retail investors after the company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million, which will support its adoption of a digital asset treasury strategy.The firm stated that the principal holding will be the native utility token of the Aethir ecosystem.The two private transactions are expected to close on or about October 2. The funds will be used to support the company’s digital asset treasury strategy, for the acquisition of ATH in the open market, and for working capital and general corporate purposes, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-inc-announces-private-placements-344-million">stated</a>.Last week, Predictive Oncology also <a href="https://stocktwits.com/news-articles/markets/equity/predictive-oncology-shares-tumble-on-reverse-stock-split-announcement/chDl1r4R3IR">announced</a> a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, which became effective at 12:01 a.m. on Tuesday, Sept. 30, 2025. The split is designed to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange. Following the split, the company lowered its shares of common stock to 762,000 from over 11.4 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of Dec. 31, 2024, and a stockholders' deficit of approximately $1.7 million.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spotify-stock-is-slipping-2-in-premarket/chDDP1nR3Bg">Why Spotify Stock Is Slipping 2% In Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Predictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important Developments

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.

Equity

The company on Monday announced the pricing of two private placement transactions to raise an aggregate of approximately $344.4 million.


Shares of Predictive Oncology Inc. (POAI) tumbled 19% on Thursday after the company announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock.The reverse stock split will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156239/37244/en/Predictive-Oncology-Announces-1-for-15-Reverse-Stock-Split.html">become</a> effective at 12:01 a.m. on Tuesday, September 30, the company said. The reverse stock split is primarily aimed at bringing the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the bourse.At the effective time of the reverse stock split, every 15 shares of Predictive Oncology’s issued and outstanding common stock will be combined automatically into one share of common stock. While the company currently has over 11.4 million shares of common stock, it will be reduced to about 762,000 after the split, the firm added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/POAI">POAI stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_2_16_32_PM_png_9c3fdd1117.webp" alt="POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>POAI's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock will fall below $0.50 before the reverse stock split becomes effective.<stembedurl>https://stocktwits.com/MillionaireTrader555/message/629988968</stembedurl>Predictive Oncology is an AI-driven drug development and discovery company. For the second quarter, the company reported diluted loss per common share of $0.22. The company ended the quarter with $506,078 in cash and cash equivalents, compared to $611,822 as of December 31, 2024, and a stockholders' deficit of approximately $1.7 million.POAI stock is up 17% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiziana-life-sciences-stock-rises-on-advancing-second-asset/chDl0MtR34z">Tiziana Life Sciences Shares Rise On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Shares Tumble 19% On Reverse Stock Split Announcement – More Details Inside

The reverse stock split is primarily intended to bring the company into compliance with Nasdaq’s minimum bid requirement for continued listing on the exchange.

Shares of Predictive Oncology Inc. (POAI) fell to their lowest level in a month on Thursday, drawing&nbsp;significant retail attention. Renovaro announced that its 2025 lawsuit to enforce a merger agreement with POAI will proceed on an expedited trial schedule.Renovaro, a TechBio company specializing in diagnostics and genetically enhanced cancer therapies, said the Delaware Court of Chancery approved its motion to fast-track a&nbsp;lawsuit filed earlier this month.&nbsp;Predictive Oncology shares closed down 10.1% at $0.98 on Thursday, holding steady in after-hours trading.The case stems from an alleged breach of a binding merger agreement signed on Jan. 1.According to Renovaro’s complaint, the agreement required POAI to merge into Renovaro in exchange for a new class of preferred stock.&nbsp;Renovaro claims that Predictive Oncology violated exclusivity and good faith clauses by raising $545,000 in a public offering in February and attempting to terminate the agreement unilaterally in April.The company&nbsp;now seeks specific performance, injunctive relief, and damages for the alleged breaches.In its Form 10-Q filing dated May 14, Predictive Oncology said that while the two companies entered into a binding letter of intent for the merger on Jan. 1, and extended the agreement’s termination date to March 31, no definitive purchase agreement was signed by that date.&nbsp;Predictive Oncology’s board notified Renovaro on April 3 that merger discussions were discontinued and that the company has no further obligations under the letter of intent or extension agreement.&nbsp;The company dismissed Renovaro’s lawsuit as without merit and said it intends to “vigorously” contest the case.The dispute unfolds as Predictive Oncology continues to promote its use of AI and machine learning in drug discovery, citing access to a biobank of over 150,000 live tumor samples.&nbsp;The company said its platform modeled tumor responses for 21 previously untested compounds.On Stocktwits, retail sentiment was ‘bullish’ amid a 2,200% surge in 24-hour message volume.One retail user said they held no position in POAI but were invested in Renovaro and hoped the merger would be completed.&nbsp;<stembedurl>https://stocktwits.com/Stengaard1/message/615590359</stembedurl>Another user suggested POAI could deliver unexpected gains, predicting the stock might rally suddenly.<stembedurl>https://stocktwits.com/EarlofLondon/message/615526666</stembedurl>The stock has risen 6.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish

Renovaro said the Delaware Court of Chancery had approved an expedited trial schedule for the lawsuit it filed to enforce a binding merger agreement with Predictive Oncology.

Axe Compute, Inc. engages in the application of artificial intelligence medicine and the provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment consists of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Axe Compute Inc.

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

POAI
Predictive Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest POAI News

POAIPredictive Oncology Inc